

Memorandum
April 14, 2003

TO: Pharmacists

FROM: Barbara A. Bradford, R.N.
Chief, Kidney Disease Program

RE: Kidney Disease Program Reimbursable Drug List

.....

Kidney Disease Program (KDP) regulations (COMAR 10.20.01.08) mandate that pharmaceutical manufacturers provide a drug rebate to the Program for KDP recipient purchases of drugs. Ten (10) pharmaceutical manufacturers have declined to participate in the KDP Drug Rebate Program.

The KDP has initiated steps to remove the following labeler codes and their NDC codes and from the Maryland Kidney Disease Program Formulary ONLY:

| | |
|----------------------------------|--|
| Abbott Laboratories | 00044, 00074 |
| Merck & Co., Inc. | 59591, 00006 |
| Wyeth-Ayerst Laboratories | 53124 |
| Tap Pharmaceuticals Inc. | 00300 |
| Warrick Pharmaceuticals | 59930 |
| Sanofi-Synthelabo Inc. | 00024, 00563, 00955, 08024 |
| Upsher-Smith Laboratories | 00245, 00832 |
| Monarch Pharmaceuticals | 59229, 61570 |
| Wyeth | 00005, 00008, 00031, 00046, 00205, 00206, 00573, 00641, 57706, 58394, 59911 |
| Schering Corporation | 00085 |

The cessation of KDP coverage for the above labeler codes and their NDC codes will become effective as of the date on which First Data Bank removes those codes from the KDP Reimbursable Drug List.

Please direct any questions you may have to Mrs. Sheila Stein @ 410-767-5006 or Mrs. Della Harris @ 410-767-5010 for any questions you may have.

